Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
28
02
2023
accepted:
26
07
2023
revised:
12
07
2023
medline:
6
11
2023
pubmed:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
The current incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers were studied. All centers that had performed allogeneic HSCTs in adult patients within one defined year were invited to the study. Seventy-one centers participated with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The cumulative incidence of VOD/SOS at day 21 was 1.8% and at day 100 2.4%. Of 67 cases with detailed data, 52 were classical and 15 (22%) late onset (>day 21). According to the EBMT criteria, 65/67 patients had at least two VOD/SOS risk factors. The severity grades were: mild 0, moderate 3, severe 29, very severe 35. Fifty-four patients were treated with defibrotide. VOD/SOS resolved in 58% of the patients, 3/3 with moderate, 22/28 with severe, and 12/33 with very severe grade (p < 0.001). By day 100, 57% of the patients were alive; 3/3 with moderate, 22/29 with severe, and 13/35 with very severe VOD/SOS (p = 0.002). In conclusion, the incidence of VOD/SOS was low. Severe and very severe grades dominated. Very severe grade predicted poor outcome compared to severe grade further supporting the concept of early diagnosis and treatment to avoid a dismal outcome.
Identifiants
pubmed: 37573397
doi: 10.1038/s41409-023-02077-2
pii: 10.1038/s41409-023-02077-2
pmc: PMC10622315
doi:
Substances chimiques
Polydeoxyribonucleotides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1214Informations de copyright
© 2023. The Author(s).
Références
Br J Haematol. 2018 Jun;181(6):816-827
pubmed: 29767845
Biol Blood Marrow Transplant. 2018 Oct;24(10):2072-2080
pubmed: 29928989
Bone Marrow Transplant. 2019 Dec;54(12):1951-1962
pubmed: 30804485
Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68
pubmed: 19766729
Bone Marrow Transplant. 2019 Aug;54(8):1361-1368
pubmed: 30809031
Front Immunol. 2020 Apr 03;11:489
pubmed: 32318059
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Expert Rev Gastroenterol Hepatol. 2017 Oct;11(10):885-898
pubmed: 28825848
Bone Marrow Transplant. 2014 Nov;49(11):1389-92
pubmed: 25068424
Blood Adv. 2022 Jan 11;6(1):181-188
pubmed: 34666352
Br J Haematol. 2020 Sep;190(6):822-836
pubmed: 32133623
Bone Marrow Transplant. 2016 Jul;51(7):906-12
pubmed: 27183098
Biol Blood Marrow Transplant. 2011 Nov;17(11):1713-20
pubmed: 21708110
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Bone Marrow Transplant. 2018 Feb;53(2):138-145
pubmed: 28759025
Br J Haematol. 2017 Jul;178(1):112-118
pubmed: 28444784
Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54
pubmed: 18022574
Bone Marrow Transplant. 2021 Apr;56(4):917-927
pubmed: 33208915
Bone Marrow Transplant. 2015 Jun;50(6):781-9
pubmed: 25798682